Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Pautier

Showing results (131-140 of 149) with videos related to

Pageof 15
Sort By:
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 8, 2017
Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network settingI Ray-Coquard, AnnaLisa Trama, M J Seckl, et al.
Gynecologic Oncology|October 15, 2021
Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 studyF Gernier, A Gompel, C Rousset-Jablonski, et al.
Gynecologic Oncology|November 24, 2018
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12F Heitz, P Harter, E Åvall-Lundqvist, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2019
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)P Pautier, N Penel, I Ray-Coquard, et al.
Gynecologie, Obstetrique & Fertilite|May 22, 2008
[Initial management of gynecologic cancers: reference guides of the Société Française d'Oncologie Gynécologique (SFOG) ]D Querleu, P Bonnier, P Morice, et al.
ESMO Open|July 29, 2021
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgeryP Pautier, A Floquet, C Chevreau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2017
Networking for ovarian rare tumors: a significant breakthrough improving disease managementN Chiannilkulchai, P Pautier, C Genestie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD IK N Moore, A M Oza, N Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 10, 2012
A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma GroupP Pautier, A Floquet, L Gladieff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 30, 2022
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trialJ S Frenel, J W Kim, N Aryal, et al.
Pageof 15

Showing results (131-140 of 149) with videos related to

Sort By:
Pageof 15
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 8, 2017
Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network settingI Ray-Coquard, AnnaLisa Trama, M J Seckl, et al.
Gynecologic Oncology|October 15, 2021
Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 studyF Gernier, A Gompel, C Rousset-Jablonski, et al.
Gynecologic Oncology|November 24, 2018
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12F Heitz, P Harter, E Åvall-Lundqvist, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2019
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)P Pautier, N Penel, I Ray-Coquard, et al.
Gynecologie, Obstetrique & Fertilite|May 22, 2008
[Initial management of gynecologic cancers: reference guides of the Société Française d'Oncologie Gynécologique (SFOG) ]D Querleu, P Bonnier, P Morice, et al.
ESMO Open|July 29, 2021
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgeryP Pautier, A Floquet, C Chevreau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2017
Networking for ovarian rare tumors: a significant breakthrough improving disease managementN Chiannilkulchai, P Pautier, C Genestie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD IK N Moore, A M Oza, N Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 10, 2012
A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma GroupP Pautier, A Floquet, L Gladieff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 30, 2022
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trialJ S Frenel, J W Kim, N Aryal, et al.
Pageof 15